Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
The goals of this study are to study MMFS-202-302 in a double blind, randomized,
placebo-controlled 9-week study of its effect on ameliorating cognitive deficits in 60
patients with schizophrenia or schizoaffective disorder with stable levels of positive
symptoms. Secondary end points will include changes in positive and negative symptoms. One
dose of MMFS-202-302 will be studied and compared with placebo as adjunctive treatment to
atypical antipsychotic drug treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Northwestern University
Collaborators:
Brain & Behavior Research Foundation Neurocentria, Inc Neurocentria, Inc.